Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT00095784 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.
MinorStudy sites: 11 to 14Interventions: decitabine (Drug) to Decitabine (Drug), Laboratory Biomarker Analysis (Other) · Eligibility criteria expanded, about 276 words · Study description expanded, about 66 wordsv38Show all 4 changesShow less
Interventions: decitabine (Drug) to Decitabine (Drug), Laboratory Biomarker Analysis (Other)
NotableResults first posted: Jan 5, 2015Primary endpoints revised (2) · Enrollment target: estimated 20 to confirmed 21 · Secondary endpoints expanded, about 30 wordsv37Show all 4 changesShow less
MinorTrial status: Recruiting to Active, Not RecruitingPrimary completion date changed from estimate of Jan 2100 to Jul 2008 · Site details revised at 11 of 11 sitesv36Show all 3 changesShow less
Primary completion date changed from estimate of Jan 2100 to Jul 2008
Site details revised at 11 of 11 sites
NotableLead sponsor: University of Chicago to National Cancer Institute (NCI)Primary completion date: Jul 2005 to Jan 2100 · Primary endpoints revised (2) · Eligibility criteria shortened, about 45 words · 4 morev35Show all 8 changesShow less
Stopped: an ongoing trial was terminated, suspended or withdrawn.
Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This phase II trial studies the side effects and how well decitabine works in treating patients with myelofibrosis, a cancer of the blood system associated with fibrosis (scar tissue) in the bone marrow that is advanced and for which there is no standard therapy. Decitabine may block the actions of some proteins that are responsible for turning certain genes off in various cancers including myelofibrosis.